Form 4: Cryoport Executive Mark Sawicki Reports Stock Transactions
SEC Form 4 Filing
Mark Sawicki, Chief Scientific Officer of Cryoport, Inc., reports the conversion of restricted stock rights and subsequent sale of shares to cover taxes.
Summary
- On March 9, 2025, Mark Sawicki, Chief Scientific Officer of Cryoport, Inc., converted 2,667 restricted stock rights into common stock.
- Following the conversion, on March 10, 2025, Sawicki sold 1,583 shares of common stock at a price of $4.8791 per share.
- The sale was conducted to cover taxes due upon the vesting of the restricted stock rights, in accordance with the Issuer's policies.
- After these transactions, Sawicki beneficially owns 78,528 shares of Cryoport, Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by an executive, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 03/09/2022 | Beginning of vesting of restricted stock rights in four equal annual installments |
| 03/09/2025 | Conversion of 2,667 restricted stock rights to common stock |
| 03/10/2025 | Sale of 1,583 shares of common stock at $4.8791 per share |
| 03/11/2025 | Date of signature for the SEC Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.